StockNews.AI
ZBIO
StockNews.AI
119 days

Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses

1. Cohen Milstein investigates potential securities fraud involving ZBIO's 2024 IPO. 2. ZBIO overstated its financial runway, leading to a significant stock drop. 3. Stock fell nearly 49% post-admission of funding limitation. 4. Legal claims are open until June 16, 2025, for affected investors. 5. Cohen Milstein has a strong track record in securities litigation.

4m saved
Insight
Article

FAQ

Why Bearish?

The substantial drop in stock price post-admission reflects severe investor distrust. Historical instances show similar fraud allegations cause long-term declines in affected stocks.

How important is it?

Legal investigations can lead to further declines in stock value, drawing significant media attention. The ongoing nature of litigation validates potential impacts on stock trading behavior.

Why Short Term?

Immediate legal actions create urgency in the next few months, impacting market perception. Previous cases show short-term stock reactions to litigation announcements.

Related Companies

ZRANZGNXKURA
WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who acquired shares in the company’s September 2024 initial public offering (“IPO”). The firm urges affected investors to contact the firm promptly to discuss their legal rights and recovery options. [Click here for information about joining the class action] Or investors should reach out to Molly J. Bowen, a partner in Cohen Milstein’s Securities Litigation & Investor Protection practice at (202) 408-4600 or mbowen@cohenmilstein.com. Allegations of Misleading Disclosures:A class action lawsuit recently filed in the U.S. District Court for the District of Massachusetts alleges that Zenas BioPharma and key stakeholders—executives, board members, and IPO underwriters—violated federal securities laws by overstating the company’s financial runway in its Registration Statement. Zenas BioPharma priced its IPO at $17.00 per share, selling more than 13.2 million shares to the public. However, just weeks later, the company admitted in its third quarter 2024 SEC filing that it could fund operations for only 12 months—half the 24-month period initially projected. This admission triggered a steep drop in Zenas’ stock, which closed at $8.72 on April 15, 2025, down nearly 49% from the offering price. Important Deadline:Investors who purchased shares pursuant and/or traceable to Zenas BioPharma’s IPO and experienced significant losses have until June 16, 2025, to file a motion for appointment as lead plaintiff. Lead plaintiffs act on behalf of all class members in overseeing the litigation. Participation is not required to share in any potential recovery. About Cohen Milstein:Cohen Milstein is one of the nation’s leading plaintiffs’ law firms, with a deep track record in securities litigation. With more than 100 attorneys in eight offices, the firm has secured billions for defrauded investors and is consistently recognized by The Legal 500, Law360, Chambers USA, and The National Law Journal for excellence in securities law. In 2024 alone, Cohen Milstein helped recover over $1 billion as co-lead counsel in In re Wells Fargo & Company Securities Litigation. For more information, visit www.cohenmilstein.com. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Molly Bowen, Esq.Licensed in DC, Florida, and OhioCohen Milstein Sellers & Toll PLLC1100 New York Avenue, N.W., Fifth FloorWashington, D.C. 20005T: (888) 240-0775 or (202) 408-4600E: mbowen@cohenmilstein.comW: www.cohenmilstein.com

Related News